The renowned global medical device company has a market capitalization of $214.01 million. The company projects 18.6% growth over the next five years. Nevro’s earnings surpassed the Zacks Consensus ...
At Regenerative Neuropathy of O’Fallon, Illinois, highly trained doctors are using a cutting-edge treatment and successfully slowing and often reversing the disease without addictive medications. The ...
Approval based on positive results from the IMROZ phase 3 study demonstrating Sarclisa in combination with bortezomib, lenalidomide, and dexamethasone (VRd) significantly improved progression-free ...